Association of serum uric acid level with mortality and morbidity of patients with acute ST-elevation myocardial infarction

Reza Hajizadeh1, Samad Ghaffari1*, Rezvanieh Salehi1, Sarvin Mazani2, Sharmin Aghavali2

1Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Abstract

Introduction: Investigating the clinical impact of serum uric acid (UA) and its lowering agents on the complications and mortality of acute ST-elevation myocardial infarction (STEMI) can open a new era in STEMI treatment. The aim of this study was to evaluate the effect of on admission serum UA level on the mortality and morbidity of patients admitted with STEMI.

Methods: A number of 608 patients with STEMI were enrolled in this study from December 21, 2012 until February 19, 2014. Patients were followed for 20 months. Male to female ratio was 2.53, and the mean age of patients was 62.6±13.4. The relationship between the level of UA and patients’ mortality and morbidity, left ventricular ejection fraction (LVEF), atrial and ventricular arrhythmia was analyzed.

Results: Patients with high serum UA level had higher Killip class after STEMI (P=0.001). Mean LVEF was measured to be 39.5±9.6 in normal UA group and 34.6±11.6 in high UA group (P=0.001). In comparison with normal UA group, high UA group had significantly higher cTnI (2.68±0.09 vs 4.09±0.42, respectively, P=0.001), increased blood pressure (P=0.009), and higher atrial fibrillation (AF) occurrence (P=0.03), but no association was seen between ventricular tachycardia and serum UA level. Short term and midterm mortality were not different in two groups (P=0.44 and 0.31, respectively).

Conclusion: In the current study, high serum UA level in patients with acute myocardial infarction (MI) was not associated with higher in-hospital or midterm mortality, but it was associated with lower LVEF, higher Killip class, elevated cTnI, creatinine, triglyceride, and higher AF.

Please cite this article as: Hajizadeh R, Ghaffari S, Salehi R, Mazani S, Aghavali S. Association of serum uric acid level and mortality with morbidity of patients with acute ST-elevation myocardial infarction. J Cardiovasc Thorac Res 2016;8(2):56-60. doi: 10.15171/jcvtr.2016.11.

Introduction

Ischemic heart disease (IHD) with 7.4 million deaths and hypertension with 1.1 million deaths per year have been a major cause of mortality during the past decade.1 Recent investigations have shown a high incidence of all cardiovascular diseases especially MI in Iran.2,3 Better understanding of the pathophysiology of disease and prognostic biomarkers can result in better treatment of patients. Intra-coronary thrombosis formation can cause coronary artery blood flow occlusion, which results in MI. Irreversible myocardial damage and cell death would occur if occlusion of coronary artery lasts more than 20 minutes.4 Adenosine produced by cardiac myocytes causes the vasodilatation of arteries. The level of adenosine is increased under some conditions such as hypoxia and tissue ischemia.5 Endothelium degrades adenosine to uric acid (UA) rapidly; so due to increasing the concentration of UA and decreasing the intracellular PH, rapid UA efflux to the vascular lumen occurs.6 hence, UA level may be an indicator of severity of ischemia and tissue hypoxia and high serum UA has been stipulated as a risk factor for coronary artery disease (CAD) and somehow as prognostic factor for mortality and morbidity in patients with CAD. Chen et al showed association between serum UA and adverse events in patients with STEMI.7 Kroll et al showed that in patients with higher on admission serum UA, short term and long term mortality was increased.8 In other study done in Iran higher serum UA had association with in-hospital and short term mortality.9 By developing new treatments especially increasing trend to invasive therapy in high risk patients for example those who develop heart failure after ST-elevation myocardial infarction (STEMI) and continuous effort to decrease STEMI mortality, it is interesting to investigate whether prognostic factors such as serum UA continue to have their prognostic value or not.

*Corresponding author: Samad Ghaffari, Email: ghafaris@gmail.com

© 2016 The Author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In this study, we investigated on admission serum UA levels as a potential predictor of in-hospital and 20 months follow up period mortality and morbidity in patients with MI.

**Patients and Methods**

**Study design and setting**

The aim of this cross-sectional study was to evaluate the effect of on admission serum UA on the short term and mid-term mortality and morbidity of patients admitted with STEMI. We studied 608 patients admitted from December 21, 2012 till February 19, 2014 at Shahid Madani hospital, Tabriz, Iran. Patients were divided into two groups according to their serum UA level.

**Inclusion and exclusion criteria**

Patients with STEMI were enrolled in this study. Acute MI was defined as presence of ST-segment elevation consistent with the MI at least 2 mm in adjacent chest leads and/or ST-segment elevation at least 1 mm in 2 or more standard leads or new left bundle branch block, concordant with positive cardiac necrosis markers. Hypertension was interpreted as blood pressure ≥140/90 or taking anti-hypertensive medications. Having fasting blood glucose level higher than 126 mg/dL or having a random blood glucose test level of 200 mg/dL or higher as well as those taking medications for hyperglycemia were defined as diabetes. Hyperlipidemia was defined as cholesterol level ≥200 mg/dL and triglyceride ≥250 mg/dL. Patients with liver disease, progressive kidney disorders (creatinine >1.8), gout, alcoholism or taking antihyperuricemic drugs were excluded. Patients with previous history of diuretic and losartan use, also patients with previous history of MI, were excluded.

**Study protocol**

Blood samples were taken as soon as possible after admission. Laboratory data was gathered and UA level measured according to the standard procedures of our laboratory at Madani heart hospital, Tabriz, Iran. High UA level was defined as more than 8 mg/dL in men and more than 7.5 mg/dL in women. Transthoracic echocardiography was used to evaluate LVEF.

**Statistical analyses**

SPSS version 17.0 was used for statistical analysis. Continuous data were expressed as mean ± SD/SE. The t test was used to compare continuous variables and Chi-square test was used to compare qualitative variables. UA and lipid profiles relationships were calculated with Pearson correlation coefficients. P value <0.05 was considered significant.

With a sample size of 608 patients and based on previous studies the statistical power of this study calculated to be 90%.

**Results**

In this cross-sectional study, we enrolled 608 patients with definite diagnosis of STEMI. Male to female ratio was 2.53, the mean age of patients was 62.6 ± 13.4, and patients were divided into two groups according to their serum UA level. Table 1 shows the demographic, medical, and drug history of patients according to their serum UA level. Patients with high UA had higher Killip class after STEMI (P=0.001). Figure 1 shows the Killip class differences in two groups. Regarding the STEMI risk factors, smoking was more common in normal UA group (P=0.02), but increased blood pressure was seen more frequently in high UA group (P=0.009), and diabetes mellitus and cholesterol level were not different in two groups (P=0.57 and 0.81, respectively).

In comparison with normal UA group, high UA group had significantly higher cTnI (2.68 ± 0.09 vs 4.09 ± 0.42, respectively with a range of 0-14, median=2, and P=0.001) and higher creatinine level (P=0.001). Table 2 shows the paraclinical values of patients according to their serum UA concentrations. Mean LVEF was measured 39.5 ± 9.6 in normal and 34.6 ± 11.6 in high UA group (P=0.001).

We found that serum UA level was associated with higher AF occurrence (P=0.03), but no association was observed between the serum UA level and ventricular tachycardia. Short term and midterm mortality (average follow up was 20 months) were not different between two groups (P=0.44 and 0.31, respectively). Table 3 shows the complications and management of patients during the hospital course.

**Discussion**

Some studies have shown that in patients with MI, high serum UA level can increase the mortality rate. In the current study, we could not find this association and according to patients’ serum UA level, in-hospital mortality and midterm mortality were not different between two groups.
Kojima et al divided patients according to their serum UA level into four groups. Patients whose serum UA level was more than 399 µmol/L had 3.7 times higher total mortality rate than those with a serum UA level below 274 µmol/L. In this study, mean age of patients (67 years old) was higher than that of our study (62 years old).

In addition, previous studies revealed that high serum UA level in patients with MI accompanied poor clinical prognosis such as heart failure, low LVEF, and high LV end diastolic diameter (LVEDD).

In epidemiologic studies, high UA level has been established as a risk factor for the cardiovascular disease. In this study, we showed the association between high UA level and serum Cr and triglyceride levels. Tuomilehto et al and Nagahama et al reported similar results. Nagahama et al showed positive correlation between increased serum UA level and obesity, increased blood pressure and dyslipidemia. Also Chen et al showed a significant association between UA level and dyslipidemia. In this study, no correlation was found between high serum UA level and hypercholesterolemia.

We found that higher UA level had association with higher AF occurrence. Similarly Huang et al and Tamariz et al reported higher UA level in patients with AF rhythm. Huang et al showed that in patients with AF who had not obstructive CAD, coronary blood flow had independent association with serum UA level.

Pozzoli et al showed that the onset of AF in patients with heart failure and sinus rhythm was associated with significant worsening in patients’ NYHA functional class. Mai sel et al showed that incidence of AF was increased significantly in patients with more severe heart failure. However, we did not evaluate the frequency of arrhythmias using Holter monitoring and our arrhythmia evaluation was focused on sustaining the symptomatic arrhythmias.

In this study a significant correlation was found among high serum UA level, low LVEF, and higher Killip class, and Patients with high serum UA level were older, and had higher creatinine. These factors may be responsible for lower percutaneous coronary intervention (PCI) therapy and subsequently higher Killip class in these patients. There are other hypotheses about how high UA level is associated with low LVEF. One of these mechanisms focuses on the impact of UA on the efficacy of thrombolysis. Purine catabolism produces UA by the act of xanthine oxidase enzyme. UA is released in hypoxic conditions. In patients who develop heart failure after MI, tissue hypoperfusion and hypoxia lead to the activation of xanthine oxidase and other oxidative products. Viña et al reported that the xanthine oxidase is responsible for free radical production. They showed that tissue damage can be caused by the xanthine oxidase activity during heavy exercise. In their study allopurinol could reduce the oxidation of glutathione. Moreover, free radicals might be responsible for the inefficacy of re-perfusion therapy. Serum UA level can predict coronary blood flow in patients with acute STEMI treated with primary PCI.

### Table 2. Comparison of paraclinical values of patients according to their serum UA level

|                         | Total 608 (100%) | Low UA group 518 (85.2%) | High UA group 90 (14.8%) | P value |
|-------------------------|------------------|--------------------------|--------------------------|---------|
| Cholesterol >200 mg/dL  | 212 (34.9%)      | 184 (35.5%)              | 30 (33.3%)               | 0.811   |
| Cholesterol value*      | 237±30.1         | 238±29.7                 | 232±32.3                 |         |
| TG >250                 | 53 (8.7%)        | 39 (7.5%)                | 14 (15.5%)               | 0.023   |
| TG value*               | 381±121.6        | 366±113.0                | 423±138.7                |         |
| CPK**                   | 693±57.6 (median:259) | 625±241.1 (median: 256) | 1104±319.9 (median: 341) | 0.001   |
| CPK-MB**                | 92.3±16.8 (median:52.5) | 90.0±7.5 (median: 52)   | 102.3±16.4 (median:55.5) | 0.001   |

**Abbreviations:** TG, triglycerides; CPK, creatine phosphokinase.

*Mean ± standard deviation, ** mean ± standard error.

### Table 3. Complications and management of patients during the hospital course

|                     | Total 608 (100%) | Low UA group 518 (85.2%) | High UA group 90 (14.8%) | P value |
|---------------------|------------------|--------------------------|--------------------------|---------|
| Thrombolytic therapy| 215 (35.3%)      | 187 (36.1%)              | 28 (31.1%)               | 0.361   |
| Primary PCI         | 453 (74.5%)      | 402 (77.6%)              | 51 (56.6%)               | 0.001   |
| VT/VF               | 29.4%            | 24 (4.6%)                | 5 (5.5%)                 | 0.602   |
| In-hospital death   | 38 (6.2%)        | 34 (6.5%)                | 4 (4.4%)                 | 0.443   |

**Abbreviations:** PCI, percutaneous coronary intervention; VT, ventricular tachycardia; VF, ventricular fibrillation; UA, uric acid.

### Figure 1. Killip class of patients according to their serum UA level.
reported that IL-1 induced free radicals stimulate PAI-1 in rats. In addition, they suggested that inhibition of fibrinolysis may be responsible for the serious cardiac dysfunction after the ischemia. However, the exact effect of fibrinolysis on the free radicals production is not clearly understood.

Kaya et al showed that elevated serum UA level on admission was an independent factor of short term and long term adverse events in patients with STEMI who were treated with primary percutaneous angiography. Evaluating the efficacy of some medications to reduce oxidative stress (e.g., xanthine oxidase inhibitors) after thrombolytic therapy may be helpful and we need large prospective studies to evaluate the effect of serum UA lowering agents in reducing adverse events in patients who develop acute STEMI. These findings suggest that, serum UA level can be used as a prognostic factor in MI patients.

Limitations
This study had some limitations. We did not have 24-hour electrocardiogram (ECG) monitoring and our data only consisted of sustained AF and VT. Because of small number of patients who developed arrhythmia, more investigations with larger sample size can help in better evaluation of association of AF and VT and serum UA level. Finally because IHD is a chronic disease, long term follow-up is needed for better evaluation of long term effects of UA on the cardiovascular system.

Conclusion
In the current study, high serum UA level in patients with acute MI was not associated with higher in-hospital or midterm mortality rate. However, high serum UA level was associated with lower LVEF, higher Killip class and AF, elevated cTnI, creatinine, and triglyceride level.

Acknowledgments
We would like to thank all the patients, nurses, and doctors of Shahid Madani heart center.

Ethical Approval
This study approved by the local ethical committee.

Competing of interests
None to be declared.

References
1. WHO. The 10 leading causes of death in the world, 2000 and 2011. Geneva: WHO; 2014.
2. Talaei M, Sarrafzadegan N, Sadeghi M, Oveisgharan S, Marshall T, Thomas GN, et al. Incidence of cardiovascular diseases in an Iranian population: the Isfahan cohort study. Arch Iran Med. 2013;16(3):138-44.
3. Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol. 2013;168(2):934-45. doi: 10.1016/j.ijcard.2012.
4. Soukoulis V, Boden WE, Smith SC Jr, O’Gara PT. Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon. Circ Res 2014; 114: 1944-58. doi: 10.1161/circresaha.114.302804
5. Raatikainen MJ, Peuhkurinen KJ, Hassinen IE. Contribution of endothelium and cardiomyocytes to hypoxia-induced adenosine release. J Mol Cell Cardiol 1994; 26: 1069-80. doi: 10.1006/jmcc.1994.1127
6. Kroll K, Bukowski TR, Schwartz LM, Knoopfier D, Bassingthwaighte JB. Capillary endothelial transport of uric acid in guinea pig heart. Am J Physiol 1992; 262: H240-31.
7. Chen L, Li XL, Qiao W, Ying Z, Qin YL, Wang Y, et al. Serum uric acid in patients with acute ST-elevation myocardial infarction. World J Emerg Med 2012; 3: 35-9. doi: 10.5847/wjem.j.1920-8642.2012.01.006
8. Car S, Trkulja V. higher serum uric acid on admission is associated with higher short-term mortality and poorer long-term survival after myocardial infarction: retrospective prognostic study. Croatian Medical Journal 2009; 50: 559-66. doi: 10.3325/cmj.2009.50.559
9. Omidvar B, Ayatollahi F, Alasti M. The prognostic role of serum uric acid level in patients with acute ST elevation myocardial infarction. J Saudi Heart Assoc 2012; 24: 73-8. doi: 10.1016/j.jsha.2012.01.005
10. Polonski L, Gasior M, Gierlotka M, Kalarus Z, Cieslinski A, Dubiel JS, et al. Polish Registry of Acute Coronary Syndromes (PL-ACS). Characteristics, treatments and outcomes of patients with acute coronary syndromes in Poland. Kardiol Pol 2007; 65: 861-72.
11. WHO. Q&As on hypertension. http://www.who.int/features/qa/82/en/. Published 2015.
12. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes care 2008; 31: S55-S60.
13. Hueston WJ, Pearson WS. Subclinical hypothyroidism and the risk of hypercholesterolemia. Ann Fam Med 2004; 2: 351-5.
14. Agudelo CA, Turner RA, Panetti M, Pisko E. Does hyperuricemia protect from rheumatoid inflammation? A clinical study. Arthritis Rheum 1984; 27: 443-8.
15. Kojima S, Sakamoto T, Ishihara M, Kimura K, Miyazaki S, Yamagishi M, et al. Progostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). Am J Cardiol 2005; 96: 489-95. doi: 10.1016/j.amjcard.2005.04.007
16. Nadkar MY, Jain VI. Serum uric acid in acute myocardial infarction. J Assoc Physicians India 2008; 56: 759-62.
17. Alderman M, Aiyer K. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20: 369-79. doi: 10.1185/030079904125002982
18. Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in healthy and in coronary heart disease. Ann Intern Med 1951; 34: 1421-31.
19. Brand FN, McGee DL, Kannel WB, Stokes J, 3rd, Castelli WP. Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol 1985; 121: 11-8.
20. Tuomilehto J, Zimet P, Wolf P, Taylor R, Ram P, King H. Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol 1988; 127: 321-36.
21. Nagahama K, Iseki K, Inoue T, Tsucha T, Ikemiy Y, Takishi S. Hyperuricemia and cardiovascular risk factor clustering in a screened cohort in Okinawa, Japan. Hypertens Res 2004; 27: 227-33.
22. Huang Z, Luo C, Hu X, Feng C, Gao X. Relationship between Serum Uric Acid and Coronary Blood Flow in Patients with Atrial Fibrillation. *Metabolomics* 2015; 5: 139.

23. Tamariz L, Hernandez F, Bush A, Palacio A, Hare JM. Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis. *Heart Rhythm* 2014; 11: 1102-8. doi: 10.1016/j.hrtm.2014.04.003

24. Pozzoli M, Cioffi G, Traversi E, Pinna GD, Cobelli F, Tavazzi L. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. *J Am Coll Cardiol* 1998; 32: 197-204.

25. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. *Am J Cardiol* 2003; 91: 2d-8d.

26. Tereshchenko SN, Levchuk NN, Drozdov VN, Moiseev VS. [Level of blood uric acid in patients with postinfarction heart failure]. *Ter Arkh* 2000; 72: 57-60.

27. Hare JM, Johnson RJ. Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. *Circulation* 2003; 107: 1951-3. doi: 10.1161/01.cir.000006420.36123.35

28. Terada LS, Guidot DM, Leff JA, Willingham IR, Hanley ME, Piermattei D, et al. Hypoxia injures endothelial cells by increasing endogenous xanthine oxidase activity. *Proc Natl Acad Sci U S A* 1992; 89: 3362-6.

29. Viña J, Gimeno A, Sastre J, Desco C, Asensi M, Pallardo FV, *et al.* Mechanism of free radical production in exhaustive exercise in humans and rats; role of xanthine oxidase and protection by allopurinol. *IUBMB Life* 2000; 49: 539-44. doi: 10.1080/15216540050167098

30. Akpek M, Kaya MG, Uyarel H, Yarlioglu M, Kalay N, Gunebakmaz O, *et al.* The association of serum uric acid levels on coronary flow in patients with STEMI undergoing primary PCI. *Atherosclerosis* 2011; 219: 334-41. doi: 10.1016/j.atherosclerosis.2011.07.021

31. Okada H, Woodcock-Mitchell J, Mitchell J, Sakamoto T, Marutsuka K, Sobel BE, *et al.* Induction of plasminogen activator inhibitor type 1 and type 1 collagen expression in rat cardiac microvascular endothelial cells by interleukin-1 and its dependence on oxygen-centered free radicals. *Circulation* 1998; 97: 2175-82.

32. Kaya MG, Uyarel H, Akpek M, Kalay N, Ergelen M, Ayhan E, *et al.* Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. *Am J Cardiol* 2012; 109: 486-91. doi: 10.1016/j.amjcard.2011.09.042